bluuebunny/crossref_metadata_2025 huggingface dataset:
Abstract C069: Targeting the Bai1-driven signaling pathway as a therapeutic approach for breast cancer treatment
Authors: Odubanjo Oluwatoyin V. , Tchounwou Paul B. , Ogle Brenda M. , Noubissi Felicite K.
Published: December 2023

Breast cancer is the most prevalent cancer among women globally, and it remains the second leading cause of cancer-related mortality in this group. Notably, breast cancer exhibits a survival disparity between black and white women, with black women experiencing higher mortality rates. While the reasons for this disparity are multifaceted, differences in molecular mechanisms and signaling pathways driving disease progression may contribute to the observed survival gap. In this study, we investigate the role of cancer cell fusion-driven tumor heterogeneity and metastasis as a potential explanation for the survival disparity in breast cancer. We hypothesize that the mechanism of breast cancer fusion involves Bai1 activation-driven induction of the Elmo1/Dock 180/Rac 1 signaling pathway. Elmo1 and Dock 180 are overexpressed in breast cancer cell lines and Elmo1/Dock 180 activation is associated with breast cancer metastasis. Targeting this pathway could prevent cancer cell fusion-driven metastasis and death. To test our hypothesis, we used non-metastatic and metastatic breast cancer cells isolated from black (HCC 1806, MDA-MB-157) and white (T47D, MDA-MB-231) women, as well as mesenchymal stem cells (MSCs) (hMSC4099, hMSC39334) as fusion partners. We used Elmo1 and Dock 180 shRNAs and a Rac1 inhibitor to analyze the role of Elmo1/Dock 180/Rac 1 signaling in breast cancer cell fusion. Fusion products were scored using the Cre/loxP system. We observed that breast cancer cells isolated from black women are more prone to fuse with MSCs than cells isolated from white women (P<0.05). knocking down Bai1 significantly reduced the frequency of fusion across all cell lines (P<0.05) and more significantly in the non-metastatic breast cancer cell line isolated from black women (P<0.001). A notable reduction in the frequency of fusion between breast cancer cells and MSCs was observed when Elmo1, Dock180, or Rac1 was inhibited (P<0.05). These results suggest that the Bai1/Elmo1/Dock180/Rac1 signaling plays an important role in cancer cell fusion. Targeting this mechanism could lead to new drug development tactics for cancer treatment.

Citation Format: Oluwatoyin V. Odubanjo, Paul B. Tchounwou, Brenda M. Ogle, Felicite K. Noubissi. Targeting the Bai1-driven signaling pathway as a therapeutic approach for breast cancer treatment [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C069.
Abstract C088: circWSB1 promotes tumor progression in ccRCC via circWSB1/miR-182-5p/WSB1 axis
Authors: Tang Guyu , Liu Jing , Gao Xiaomei , Tang Wei , Chen Jiaxian , Wu Menghai , Zhang Ye , Cai Yi , Qi Lin
Published: December 2023

Background: Clear cell renal cell carcinoma (ccRCC) is one of the most prevalent urological carcinomas with a low overall 5-year survival rate, and its prognosis remains dismal. circular RNA (circRNA) has been discovered to be important regulators in ccRCC. However, the specific regulatory mechanisms of circRNA and its impact on phenotypes require further in-depth research. Methods: circRNA microarray sequencing analysis was used in this study to explore the expression pattern of circRNA in ccRCC. circWSB1 was discovered, and we evaluated its derivation, potential diagnostic efficacy, and prognostic significance in ccRCC tissues using reverse transcription quantitative polymerase chain reaction (RT-qPCR) and sanger sequencing. Fluorescence in situ hybridization analysis (FISH), RNA immunoprecipitation, and dual-luciferase reporter gene assays were used to investigate the subcellular localization and regulation mechanism of circWSB1. In vivo and in vitro loss-of-function and gain-of-function experiments were used to determine the biological functions of circWSB1. Results: Through RNA sequencing of five pairs of tumor and adjacent tissues, we discovered that circWSB1 is highly expressed in ccRCC. We identified that circWSB1 interacts with miR-182-5p and upregulates the expression of its host gene, WSB1. Through models in vivo and in vitro, we found circWSB1 increases WSB1 expression via the circWSB1/miR-182-5p/WSB1 axis, which promotes ccRCC cell proliferation and migration. The high expression of circWSB1 and WSB1 is correlated with poorer clinical prognosis and pathological grading. Conclusions: circWSB1 diminishes the inhibitory impact of miR-182-5p on WSB1, and increases WSB1 expression, thereafter promotes ccRCC development. Our findings provide a promising predictive biomarker and therapeutic target for ccRCC.

Citation Format: Guyu Tang, Jing Liu, Xiaomei Gao, Wei Tang, Jiaxian Chen, Menghai Wu, Ye Zhang, Yi Cai, Lin Qi. circWSB1 promotes tumor progression in ccRCC via circWSB1/miR-182-5p/WSB1 axis [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C088.
Abstract IA005: Persistent poverty and cancer disparities
Authors: Srinivasan Shobha
Published: December 2023

This session will highlight the challenges that persistent poverty poses for achieving health equity. In working with the US Department of Agriculture’s Economic Research Service, the NCI defines persistent poverty areas, wherein 20% or more of the population at the census tract level is below the federal poverty line based on the 1990, and 2000 decennial censuses and 2007-11 and 2015-2019 American Community Survey 5-year estimates.  Most of our research and interventions are not focused in these areas and thus do not consider these contextual factors associated with persistent poverty in addressing cancer disparities.  The three speakers will highlight the challenges and opportunities to promote research and training with communities in focusing their research on persistent poverty areas.  The speakers and titles of the talks are: NCI’s persistent poverty research agenda Amy Kennedy, National Cancer Institute, Gaithersburg, Maryland HCV screening in border areas of persistent poverty Bertha E. Flores, UT Health Science Center at San Antonio, San Antonio, Texas Relationship between measures of social determinants of health at the census tract level and cancer incidence and survival: An analysis of persistent poverty, socioeconomic index, and measures of rurality Kathy Cronin, National Institutes of Health, Bethesda, Maryland

Citation Format: Shobha Srinivasan. Persistent poverty and cancer disparities [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr IA005.
Abstract IA009: Curios case of cancer among American Indians and Alaska Natives
Authors: Henderson Jeffrey A.
Published: December 2023

Cancer incidence data published in 2008, and cancer mortality data published in 2014, both paint a picture of profound geographic variation in these rates among American Indians/Alaska Natives. Non-Hispanic whites (NHWs) living across six large geographic regions upon which both datasets were analyzed rarely exhibited geographic variation greater than 25%, with an upper limit approaching 30%. This is in distinct contrast to the AIAN population living in the same regions, who routinely exhibited geographic variation in cancer incidence rates ranging over 100% and from some cancer types in excess of 500%. These data will be shown, and subsequent consequences future priorities discussed. By the conclusion of this presentation, attendees will Gain more valuable insight about the federal Indian Health Service Be delighted to see that they can understand raw cancer data including multiple lessons regarding the profound geographic variation in AIAN cancer incidence rates Identify how they may get involved with those of us who are focused on these AIAN cancer disparities.

Citation Format: Jeffrey A. Henderson. Curios case of cancer among American Indians and Alaska Natives [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr IA009.
Abstract IA019: Implementation science as an opportunity to address cancer equity
Authors: Adsul Prajakta
Published: December 2023

The past decade of research has continued to identify and understand health disparities for cancer prevention and control. Although emerging, progress in addressing these disparities continues to fall short achieving equity. Specifically, for cancer prevention and control, Khan and colleagues in 2021 showed a 15-year lag in implementation of evidence-based interventions (i.e., HPV vaccinations, cancer screenings, etc.). This gap highlights the lack of attention towards the implementation of scientific evidence, the complexity and fragmentation of health systems, and lays bare the structural causes of inequities that continue to persist from a population perspective. Integrating implementation science in cancer prevention and control research can provide a pathway to reduce the time to translation while addressing and advancing cancer equity. Implementation science is defined as the study of methods to promote the adoption and integration of evidence-based practices, interventions, and policies into routine health care and public health settings to improve the impact on population health. Implementation science has pushed the cancer prevention and control field to pay close attention to how we dissemination scientific information towards the adoption of interventions (i.e., dissemination research) and how we systematically study strategies (i.e., the building blocks) that aid in the implementation, scale-up, and sustainability of interventions (i.e., implementation science). With implementation research, there has been a push towards hybrid designs that considers intervention effectiveness and its implementation within the same study. Given the dearth of literature around the implementation of interventions, the science of implementation continues to build on a foundational theoretical base that further provide important opportunities for the promoting equitable outcomes for cancer prevention and control research. In this educational session, we will discuss why and how applying a health equity lens to implementation science is crucial to achieve equity in cancer prevention and control. Using ongoing and completed research studies as examples, this session will help attendees learn about core elements of implementation science including theories, models, and frameworks; implementation strategies; and focal areas of adaptations and de-implementation.

Citation Format: Prajakta Adsul. Implementation science as an opportunity to address cancer equity [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr IA019.
Abstract IA030: Ensuring diversity in clinical trials
Authors: Adams-Campbell Lucile
Published: December 2023

It is well known that minorities, particularly Blacks, are underrepresented in cancer prevention, early detection, and treatment trials. However the mortality rates for Blacks are significantly higher than other race/ethnic groups.  Research suggests that community involvement is integral to solving public health problems, including involvement in clinical trials-a gold standard. Significant racial/ethnic disparities exist in the accrual of participants for clinical trials. Location and cultural aspects of clinical trials influence recruitment and accrual to clinical trials. Being able to identify and resolve social determinants of health is essential for clinical trial participation.   It is increasingly necessary to be aware of defining characteristics, such as location and culture of the populations from which research participants are enrolled. Utilizing embedded community academic sites to adapt clinical trial research in order to increase minority participation in nontherapeutic cancer clinical trials is warranted.  Considerable attention has focused on the need to increase underserved racial and ethnic populations in clinical research, especially in light of the cancer health disparities that disproportionately plague these groups.   Clinical trial design and implementation are time-consuming and require a multistep process that is complicated by other factors, including eligibility criteria for clinical trials for underserved racial and ethnic populations, recruitment processes, and patients’ misconceptions or lack of information about clinical trials. Georgetown-Lombardi National Capital Area Minority/Underserved NCORP (NCI Community Oncology Research Program) coupled with the Ralph Lauren Center for Cancer Prevention will reveal strategies and approaches instrumental to our success.  These efforts resulted in the development of a strong community capacity–building and clinical research cancer recruitment strategy, and  improved engagement of the community in clinical research, thus ensuring diversity in clinical trials.  

Citation Format: Lucile Adams-Campbell. Ensuring diversity in clinical trials [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr IA030.
Abstract IA043: The HOUSES Platform for precision cancer care and research: A cloud-based nationwide measure for next generation patient-level social determinants of health
Authors: Juhn Young
Published: December 2023

While the Joint Commission requires health care organizations (HCOs) to have plans for addressing health disparities effective in July, 2023, many HCOs were frustrated by their inability to consistently and accurately capture and apply social determinants of health (SDH) data to clinical care and research in the health ecosystem.  Dr. Young Juhn, Director of the Mayo Clinic Precision Population Science Lab (PPSL) and his team, developed and applied a standardized individual-level SDH measure derived from publically available individual housing features known as HOUSES Index.  This validated individual-level SDH measure is now available across all 50 states through the HOUSES Cloud Platform that is patient-contact free, automated, and HIPAA compliant.  The Houses Index can be made available in real time through electronic health records (EHR’s) enabling clinicians and their patients to make a shared decision for treatment options with SDH taken under consideration.  In addition, HOUSES Index is a valuable research tool for risk stratification for cancer outcomes, improving (and auditing) artificial intelligence (AI) model performance, assessing longitudinal change of SDH and geospatial patterns of outcomes, and monitoring proper representation of underserved populations in cancer research.  In this presentation, Dr. Young Juhn will discuss the current challenges for capturing SDH data in health care, the HOUSES Index and Platform as the solutions and its implications on cancer care and research.

Citation Format: Young Juhn. The HOUSES Platform for precision cancer care and research: A cloud-based nationwide measure for next generation patient-level social determinants of health [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr IA043.
Abstract PR005: Preferences of older cancer survivors for integration of remote activity monitoring using wearable devices
Authors: Morelli Whitney A. , Clohesey Kelly , Liu Jessica
Published: December 2023

Purpose: To describe the preferences for integration of wearable devices into their healthcare to remotely monitor physical activity among older adult cancer survivors. Methods: 89 cancer survivors, aged 65 and older, completed our preferences for wearable devices in healthcare questionnaire. Participants were asked to self-report demographic information, current physical activity participation, and preferences for inclusion of wearable devices as part of their care plan through a current provider (i.e. physician, physical therapist, etc.). Data are summarized and reported as mean ± standard deviation or percent. Results: Participants were on average 71±5 years old, 59% female, and mostly White, non-Hispanic (93%). 76.2% of participants reporting engaging in 0 days of vigorous intensity physical activity, with 31% reporting no moderate intensity physical activity. 59% of older cancer survivors report they already own a wearable device, with the most common device being a wrist-worn device (93%). For those that do not currently own a device, 94% report they would be interested in owning a wearable device. 94% of older cancer survivors state they would be interested in using a wearable device as part of their usual care plan for their provider to remotely monitor their health. 88% report having no privacy concerns with sharing their wearable data with their healthcare provider. Participants report they would be willing to purchase their own monitor if it meant future out of pocket healthcare costs (81%) or reduced time investment to travel to the clinic (63%). Conclusions: Results indicate older cancer survivors are interested in their care team remotely monitoring their activity levels. Further, the majority of older cancer survivors report they are willing to purchase their own device. Future research is warranted to determine an implementation plan to integrate these devices into current clinic workflows and determine optimal interaction among patients and providers.

Citation Format: Whitney A. Morelli, Kelly Clohesey, Jessica Liu. Preferences of older cancer survivors for integration of remote activity monitoring using wearable devices [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr PR005.
Table S4 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination
Authors: Dong Bo , Song Xiang , Wang Xinzhao , Dai Tao , Wang Jianlin , Yu Zhiyong , Deng Jiong , Evers B. Mark , Wu Yadi
Published: December 2023

Supplemental table 4. Tumor samples with Lymph node metastases of breast cancer.
Table S3 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination
Authors: Dong Bo , Song Xiang , Wang Xinzhao , Dai Tao , Wang Jianlin , Yu Zhiyong , Deng Jiong , Evers B. Mark , Wu Yadi
Published: December 2023

Supplemental Table S3. Tumor samples used for analysis
Table S2 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination
Authors: Dong Bo , Song Xiang , Wang Xinzhao , Dai Tao , Wang Jianlin , Yu Zhiyong , Deng Jiong , Evers B. Mark , Wu Yadi
Published: December 2023

The sequence of primers for RT-qPCR and ChIP-qPCR.
Supplementary Figure 6 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination
Authors: Dong Bo , Song Xiang , Wang Xinzhao , Dai Tao , Wang Jianlin , Yu Zhiyong , Deng Jiong , Evers B. Mark , Wu Yadi
Published: December 2023

FBXO24 expression is associated with a good prognosis.
Supplementary Figure 5 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination
Authors: Dong Bo , Song Xiang , Wang Xinzhao , Dai Tao , Wang Jianlin , Yu Zhiyong , Deng Jiong , Evers B. Mark , Wu Yadi
Published: December 2023

Association between FBXO24 expression and tumor stage and overall survival (OS) in the TCGA dataset.
Supplementary Figure 3 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination
Authors: Dong Bo , Song Xiang , Wang Xinzhao , Dai Tao , Wang Jianlin , Yu Zhiyong , Deng Jiong , Evers B. Mark , Wu Yadi
Published: December 2023

FBXO24 blocks tumor migration and invasion.
Supplementary Figure 2 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination
Authors: Dong Bo , Song Xiang , Wang Xinzhao , Dai Tao , Wang Jianlin , Yu Zhiyong , Deng Jiong , Evers B. Mark , Wu Yadi
Published: December 2023

FBXO24 degrades LSD1.
Supplemental Figure 4 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination
Authors: Dong Bo , Song Xiang , Wang Xinzhao , Dai Tao , Wang Jianlin , Yu Zhiyong , Deng Jiong , Evers B. Mark , Wu Yadi
Published: December 2023

The expression of FBXO24 is inversely associated with the expression of LSD1.
Table S2 from Competing Engagement of β-arrestin Isoforms Balances IGF1R/p53 Signaling and Controls Melanoma Cell Chemotherapeutic Responsiveness
Authors: Cismas Sonia , Pasca Sylvya , Crudden Caitrin , Trocoli Drakensjo Iara , Suleymanova Naida , Zhang Simin , Gebhard Benjamin , Song Dawei , Neo Shiyong , Shibano Takashi , Smith Terry J. , Calin George A. , Girnita Ada , Girnita Leonard
Published: December 2023

Table S2. Antibodies used in this study.
Table S1 from Competing Engagement of β-arrestin Isoforms Balances IGF1R/p53 Signaling and Controls Melanoma Cell Chemotherapeutic Responsiveness
Authors: Cismas Sonia , Pasca Sylvya , Crudden Caitrin , Trocoli Drakensjo Iara , Suleymanova Naida , Zhang Simin , Gebhard Benjamin , Song Dawei , Neo Shiyong , Shibano Takashi , Smith Terry J. , Calin George A. , Girnita Ada , Girnita Leonard
Published: December 2023

Table S1. Cell lines used in this study.
Table S6 from m6A-Mediated Biogenesis of circDDIT4 Inhibits Prostate Cancer Progression by Sequestrating ELAVL1/HuR
Authors: Kong Zhe , Lu Yali , Yang Yue , Chang Kun , Lin Yan , Huang Yan , Wang Chenji , Zhang Lu , Xu Wei , Zhao Shimin , Li Yao
Published: December 2023

RNA-seq data
Supplementary Figure 4 from Competing Engagement of β-arrestin Isoforms Balances IGF1R/p53 Signaling and Controls Melanoma Cell Chemotherapeutic Responsiveness
Authors: Cismas Sonia , Pasca Sylvya , Crudden Caitrin , Trocoli Drakensjo Iara , Suleymanova Naida , Zhang Simin , Gebhard Benjamin , Song Dawei , Neo Shiyong , Shibano Takashi , Smith Terry J. , Calin George A. , Girnita Ada , Girnita Leonard
Published: December 2023

Effect of β-arrestin imbalance on IGF1R expression
Table S5 from m6A-Mediated Biogenesis of circDDIT4 Inhibits Prostate Cancer Progression by Sequestrating ELAVL1/HuR
Authors: Kong Zhe , Lu Yali , Yang Yue , Chang Kun , Lin Yan , Huang Yan , Wang Chenji , Zhang Lu , Xu Wei , Zhao Shimin , Li Yao
Published: December 2023

circDDIT4 as miRNA sponge target genes
Supplementary Figure 3 from Competing Engagement of β-arrestin Isoforms Balances IGF1R/p53 Signaling and Controls Melanoma Cell Chemotherapeutic Responsiveness
Authors: Cismas Sonia , Pasca Sylvya , Crudden Caitrin , Trocoli Drakensjo Iara , Suleymanova Naida , Zhang Simin , Gebhard Benjamin , Song Dawei , Neo Shiyong , Shibano Takashi , Smith Terry J. , Calin George A. , Girnita Ada , Girnita Leonard
Published: December 2023

Specificity of β-arrestin1/2 siRNA effectson MDM2 localization.
Table S4 from m6A-Mediated Biogenesis of circDDIT4 Inhibits Prostate Cancer Progression by Sequestrating ELAVL1/HuR
Authors: Kong Zhe , Lu Yali , Yang Yue , Chang Kun , Lin Yan , Huang Yan , Wang Chenji , Zhang Lu , Xu Wei , Zhao Shimin , Li Yao
Published: December 2023

Biotin labeled probe.
Supplementary Figure 1 from Competing Engagement of β-arrestin Isoforms Balances IGF1R/p53 Signaling and Controls Melanoma Cell Chemotherapeutic Responsiveness
Authors: Cismas Sonia , Pasca Sylvya , Crudden Caitrin , Trocoli Drakensjo Iara , Suleymanova Naida , Zhang Simin , Gebhard Benjamin , Song Dawei , Neo Shiyong , Shibano Takashi , Smith Terry J. , Calin George A. , Girnita Ada , Girnita Leonard
Published: December 2023

Effect of β-arrestin isoform imbalance on melanoma cell viability
Supplementary Table 1 from Generating a Murine PTEN Null Cell Line to Discover the Key Role of p110β-PAK1 in Castration-Resistant Prostate Cancer Invasion
Authors: Wang Haizhen , Zhou Yu , Chu Chen , Xiao Jialing , Zheng Shanshan , Korpal Manav , Korn Joshua M. , Penaloza Tiffany , Drake Richard R. , Gan Wenjian , Gao Xueliang
Published: December 2023

Transcriptome analysis in PKO cells vs. Myc-Cap cells.
Supplementary Figure and Table Legends from Generating a Murine PTEN Null Cell Line to Discover the Key Role of p110β-PAK1 in Castration-Resistant Prostate Cancer Invasion
Authors: Wang Haizhen , Zhou Yu , Chu Chen , Xiao Jialing , Zheng Shanshan , Korpal Manav , Korn Joshua M. , Penaloza Tiffany , Drake Richard R. , Gan Wenjian , Gao Xueliang
Published: December 2023

Supplementary Figure Legends 1-5, Supplementary Table 1
Supplementary Figure 5 from Generating a Murine PTEN Null Cell Line to Discover the Key Role of p110β-PAK1 in Castration-Resistant Prostate Cancer Invasion
Authors: Wang Haizhen , Zhou Yu , Chu Chen , Xiao Jialing , Zheng Shanshan , Korpal Manav , Korn Joshua M. , Penaloza Tiffany , Drake Richard R. , Gan Wenjian , Gao Xueliang
Published: December 2023

The association of prostate cancer patients' survival rates with PAK1 expression and phosphorylation levels.
Supplementary Figure 4 from Generating a Murine PTEN Null Cell Line to Discover the Key Role of p110β-PAK1 in Castration-Resistant Prostate Cancer Invasion
Authors: Wang Haizhen , Zhou Yu , Chu Chen , Xiao Jialing , Zheng Shanshan , Korpal Manav , Korn Joshua M. , Penaloza Tiffany , Drake Richard R. , Gan Wenjian , Gao Xueliang
Published: December 2023

Antibody validation and the association analysis of PAK1/p-PAK1 with patient characteristics.
Supplementary Figure 3 from Generating a Murine PTEN Null Cell Line to Discover the Key Role of p110β-PAK1 in Castration-Resistant Prostate Cancer Invasion
Authors: Wang Haizhen , Zhou Yu , Chu Chen , Xiao Jialing , Zheng Shanshan , Korpal Manav , Korn Joshua M. , Penaloza Tiffany , Drake Richard R. , Gan Wenjian , Gao Xueliang
Published: December 2023

Related to Figure 3. p110β knockdown or inhibition reduces PTEN null prostate cancer cell migration.
Supplementary Figure 2 from Generating a Murine PTEN Null Cell Line to Discover the Key Role of p110β-PAK1 in Castration-Resistant Prostate Cancer Invasion
Authors: Wang Haizhen , Zhou Yu , Chu Chen , Xiao Jialing , Zheng Shanshan , Korpal Manav , Korn Joshua M. , Penaloza Tiffany , Drake Richard R. , Gan Wenjian , Gao Xueliang
Published: December 2023

Transcriptome expression analysis shows that PKO cells are androgen-independent.
Supplementary Table 1 from Early Immune Changes Support Signet Ring Cell Dormancy in CDH1-Driven Hereditary Diffuse Gastric Carcinogenesis
Authors: Green Benjamin L. , Gamble Lauren A. , Diggs Laurence P. , Nousome Darryl , Patterson Jesse C. , Joughin Brian A. , Gasmi Billel , Lux Stephanie C. , Samaranayake Sarah G. , Miettinen Markku , Quezado Martha , Hernandez Jonathan M. , Yaffe Michael B. , Davis Jeremy L.
Published: December 2023

Genes from RNAseq experiment comparing SRC vs. NEP.
Supplementary Figure 5 from Early Immune Changes Support Signet Ring Cell Dormancy in CDH1-Driven Hereditary Diffuse Gastric Carcinogenesis
Authors: Green Benjamin L. , Gamble Lauren A. , Diggs Laurence P. , Nousome Darryl , Patterson Jesse C. , Joughin Brian A. , Gasmi Billel , Lux Stephanie C. , Samaranayake Sarah G. , Miettinen Markku , Quezado Martha , Hernandez Jonathan M. , Yaffe Michael B. , Davis Jeremy L.
Published: December 2023

GSEA plots of carcinogenesis gene sets in SRC compared with NEP.
Table S2 from BACH1 Loss Exerts Antitumor Effects on Mantle Cell Lymphoma Cells via Inducing a Tumor-Intrinsic Innate Immune Response and Cell-Cycle Arrest
Authors: Li Guilan , Feng Min , Zhang Ziting , Liu Jiangyuan , Zhang Han
Published: December 2023

Table S2 shows the primers used for CUT&Tag-qRT-PCR.
Supplementary Figure 4 from Early Immune Changes Support Signet Ring Cell Dormancy in CDH1-Driven Hereditary Diffuse Gastric Carcinogenesis
Authors: Green Benjamin L. , Gamble Lauren A. , Diggs Laurence P. , Nousome Darryl , Patterson Jesse C. , Joughin Brian A. , Gasmi Billel , Lux Stephanie C. , Samaranayake Sarah G. , Miettinen Markku , Quezado Martha , Hernandez Jonathan M. , Yaffe Michael B. , Davis Jeremy L.
Published: December 2023

GSEA plots comparing (A) oxidative phosphorylation, (B) glycolysis, and (C) fatty acid oxidation gene sets in
SRC compared with NEP.
Supplementary Figure 2 from Early Immune Changes Support Signet Ring Cell Dormancy in CDH1-Driven Hereditary Diffuse Gastric Carcinogenesis
Authors: Green Benjamin L. , Gamble Lauren A. , Diggs Laurence P. , Nousome Darryl , Patterson Jesse C. , Joughin Brian A. , Gasmi Billel , Lux Stephanie C. , Samaranayake Sarah G. , Miettinen Markku , Quezado Martha , Hernandez Jonathan M. , Yaffe Michael B. , Davis Jeremy L.
Published: December 2023

GSEA comparing SRC to NEP using gene sets for parenchymal gastric cells.
Figure S4 from BACH1 Loss Exerts Antitumor Effects on Mantle Cell Lymphoma Cells via Inducing a Tumor-Intrinsic Innate Immune Response and Cell-Cycle Arrest
Authors: Li Guilan , Feng Min , Zhang Ziting , Liu Jiangyuan , Zhang Han
Published: December 2023

Figure S4 shows the additional GSEA analysis and the roles of Down-DEGs.
Supplementary Figure 1 from Early Immune Changes Support Signet Ring Cell Dormancy in CDH1-Driven Hereditary Diffuse Gastric Carcinogenesis
Authors: Green Benjamin L. , Gamble Lauren A. , Diggs Laurence P. , Nousome Darryl , Patterson Jesse C. , Joughin Brian A. , Gasmi Billel , Lux Stephanie C. , Samaranayake Sarah G. , Miettinen Markku , Quezado Martha , Hernandez Jonathan M. , Yaffe Michael B. , Davis Jeremy L.
Published: December 2023

Pathway analysis of Reactome database based on the variations of read depth.
Figure S3 from BACH1 Loss Exerts Antitumor Effects on Mantle Cell Lymphoma Cells via Inducing a Tumor-Intrinsic Innate Immune Response and Cell-Cycle Arrest
Authors: Li Guilan , Feng Min , Zhang Ziting , Liu Jiangyuan , Zhang Han
Published: December 2023

Figure S3 shows the Top 20 of Reactome enrichment analysis of DEGs.
Supplementary Figure 3 from Interleukin-6 Facilitates Acute Myeloid Leukemia Chemoresistance via Mitofusin 1–Mediated Mitochondrial Fusion
Authors: Hou Diyu , Zheng Xiaoming , Cai Danni , You Ruolan , Liu Jingru , Wang Xiaoting , Liao Xinai , Tan Maoqing , Lin Liyan , Wang Jin , Zhang Shuxia , Huang Huifang
Published: December 2023

The effect of STAT3 knockout on the IL-6 regulation of MFN1.
Supplementary Figure 2 from Interleukin-6 Facilitates Acute Myeloid Leukemia Chemoresistance via Mitofusin 1–Mediated Mitochondrial Fusion
Authors: Hou Diyu , Zheng Xiaoming , Cai Danni , You Ruolan , Liu Jingru , Wang Xiaoting , Liao Xinai , Tan Maoqing , Lin Liyan , Wang Jin , Zhang Shuxia , Huang Huifang
Published: December 2023

The blocking efficiency of anti-IL-6 antibody in AML mice.
Supplementary Figure 1 from Interleukin-6 Facilitates Acute Myeloid Leukemia Chemoresistance via Mitofusin 1–Mediated Mitochondrial Fusion
Authors: Hou Diyu , Zheng Xiaoming , Cai Danni , You Ruolan , Liu Jingru , Wang Xiaoting , Liao Xinai , Tan Maoqing , Lin Liyan , Wang Jin , Zhang Shuxia , Huang Huifang
Published: December 2023

The effect of MFN1 overexpression on the IL-6 mediated chemoresistance in AML.
Table S2 from AMPK Associates with Chromatin and Phosphorylates the TAF-1 Subunit of the Transcription Initiation Complex to Regulate Histone Gene Expression in ALL Cells
Authors: Sun Guangyan , Leclerc Guy J. , Chahar Sanjay , Barredo Julio C.
Published: December 2023

Antibodies used in this study.
Table S1 from AMPK Associates with Chromatin and Phosphorylates the TAF-1 Subunit of the Transcription Initiation Complex to Regulate Histone Gene Expression in ALL Cells
Authors: Sun Guangyan , Leclerc Guy J. , Chahar Sanjay , Barredo Julio C.
Published: December 2023

Chemicals used in this study.
Supplementary Methods from AMPK Associates with Chromatin and Phosphorylates the TAF-1 Subunit of the Transcription Initiation Complex to Regulate Histone Gene Expression in ALL Cells
Authors: Sun Guangyan , Leclerc Guy J. , Chahar Sanjay , Barredo Julio C.
Published: December 2023

Supplementary Methods
Figure S3 from AMPK Associates with Chromatin and Phosphorylates the TAF-1 Subunit of the Transcription Initiation Complex to Regulate Histone Gene Expression in ALL Cells
Authors: Sun Guangyan , Leclerc Guy J. , Chahar Sanjay , Barredo Julio C.
Published: December 2023

AMPKalpha1 isoform is expressed in the cytoplasmic, nuclear, and chromatin-bound fractions of CN2 cells.
Figure S2 from AMPK Associates with Chromatin and Phosphorylates the TAF-1 Subunit of the Transcription Initiation Complex to Regulate Histone Gene Expression in ALL Cells
Authors: Sun Guangyan , Leclerc Guy J. , Chahar Sanjay , Barredo Julio C.
Published: December 2023

RNA Polymerase II occupancy on the TSS region of
histone genes is decreased in Bp- and T-ALL cells in response to energy/metabolic
stress.
Data from m6A-Mediated Biogenesis of circDDIT4 Inhibits Prostate Cancer Progression by Sequestrating ELAVL1/HuR
Authors: Kong Zhe , Lu Yali , Yang Yue , Chang Kun , Lin Yan , Huang Yan , Wang Chenji , Zhang Lu , Xu Wei , Zhao Shimin , Li Yao
Published: December 2023

Abstract
The pathologic significance of the circular RNA DDIT4 (circDDIT4), which is formed by backsplicing at the 3′-untranslated region (UTR) with a 5′ splice acceptor site in exon 2 of linear DDIT4 mRNA, has yet to be determined. Our study found that circDDIT4 is downregulated in prostate cancer and functions as a tumor suppressor during prostate cancer progression. By competitively binding to ELAV-like RNA binding protein 1 (ELAVL1/HuR) through its 3′-UTR, circDDIT4 acts as a protein sponge to decrease the expression of prostate cancer–overexpressed anoctamin 7 (ANO7). This promotes prostate cancer cell apoptosis while inhibiting cell proliferation and metastasis. Furthermore, we discovered that N6-methyladenosine (m6A) modification facilitates the biogenesis of circDDIT4. The methyltransferase complex consisting of WTAP/METTL3/METTL14 increases the level of circDDIT4, while the RNA demethylase FTO decreases it.
Implications:
These findings suggest that abnormal cotranscriptional modification of m6A promotes prostate cancer initiation and progression via a circular RNA-protein-cell signaling network.
Data from Early Immune Changes Support Signet Ring Cell Dormancy in CDH1-Driven Hereditary Diffuse Gastric Carcinogenesis
Authors: Green Benjamin L. , Gamble Lauren A. , Diggs Laurence P. , Nousome Darryl , Patterson Jesse C. , Joughin Brian A. , Gasmi Billel , Lux Stephanie C. , Samaranayake Sarah G. , Miettinen Markku , Quezado Martha , Hernandez Jonathan M. , Yaffe Michael B. , Davis Jeremy L.
Published: December 2023

Abstract
Stage IA gastric adenocarcinoma, characterized by foci of intramucosal signet ring cells (SRC), is found in nearly all asymptomatic patients with germline pathogenic CDH1 variants and hereditary diffuse gastric cancer syndrome (HDGC). The molecular steps involved in initiating malignant transformation and promoting SRC dormancy in HDGC are unknown. Here, whole-exome bulk RNA sequencing (RNA-seq) of SRCs and adjacent non-SRC epithelium (NEP) was performed on laser-capture microdissected (LCM) regions of interest found in risk-reducing total gastrectomy specimens from patients with HDGC (Clinicaltrials.gov ID: NCT03030404). In total, 20 patients (6 male, 14 female) with confirmed HDGC were identified. Analysis of differentially expressed genes (DEG) demonstrated upregulation of certain individual EMT and proliferation genes. However, no oncogenic pathways were found to be upregulated in SRCs. Rather, SRC regions had significant enrichment in pathways involved in T-cell signaling. CIBERSORTx predicted significant increases in the presence of regulatory T cells (Treg) specific to SRC regions. IHC confirmed an increase in FOXP3+ cells in SRC foci, as well as elevations in CD4+ T cells and HLA-DR staining. In summary, the tumor immune microenvironment is microscopically inseparable from stage IA gastric SRCs using a granular isolation technique. An elevation in CD4+ T cells within SRC regions correlates with clinically observed SRC dormancy, while Treg upregulation represents a potential immune escape mechanism.
Implications:
Characterization of the tumor–immune microenvironment in HDGC underscores the potential for the immune system to shape the transcriptional profile of the earliest tumors, which suggests immune-directed therapy as a potential cancer interception strategy in diffuse-type gastric cancer.
Data from BACH1 Loss Exerts Antitumor Effects on Mantle Cell Lymphoma Cells via Inducing a Tumor-Intrinsic Innate Immune Response and Cell-Cycle Arrest
Authors: Li Guilan , Feng Min , Zhang Ziting , Liu Jiangyuan , Zhang Han
Published: December 2023

Abstract
BTB and CNC homology 1 (BACH1) is a transcription repressor that regulates multiple physiological processes, including intracellular heme homeostasis and immune responses. Increasing lines of evidence indicate that BACH1 reshapes metastasis and metabolism of human solid tumors. However, its potential roles in mantle cell lymphoma (MCL) remain largely unknown. Here, we found that silencing BACH1 in MCL cells induced markedly cell-cycle arrest and cell apoptosis, whereas overexpression of BACH1 exhibited the opposite patterns. Increased BACH1 levels not only promoted tumor growth and dispersal in xenografts, but also conferred a long-term poor prognosis in patients with MCL. Interestingly, RNA sequencing analysis revealed noncanonical function of BACH1 in regulation of type I interferon (IFNI) response, DNA replication and repair, and cell cycle. Mechanistically, zinc finger and BTB domain containing 20 (ZBTB20) and HMG-box transcription factor 1 (HBP1) were for the first time identified as two novel downstream targets repressed by BACH1 in MCL cells. Further double-knockdown functional assays confirmed that loss of BACH1 induced ZBTB20-mediated IFNα production and HBP1-mediated cell-cycle arrest, indicating that BACH1-centered regulatory network may be a novel targetable vulnerability in MCL cells.
Implications:
BACH1 serves as a pleotropic regulator of tumor-intrinsic innate immune response and cell-cycle progression, disruption of which may offer a promising therapeutic strategy for MCL treatment.
Data from AMPK Associates with Chromatin and Phosphorylates the TAF-1 Subunit of the Transcription Initiation Complex to Regulate Histone Gene Expression in ALL Cells
Authors: Sun Guangyan , Leclerc Guy J. , Chahar Sanjay , Barredo Julio C.
Published: December 2023

Abstract
The survival rates for relapsed/refractory acute lymphoblastic leukemia (ALL) remain poor. We and others have reported that ALL cells are vulnerable to conditions inducing energy/ER-stress mediated by AMP-activated protein kinase (AMPK). To identify the target genes directly regulated by AMPKα2, we performed genome-wide RNA-seq and ChIP-seq in CCRF-CEM (T-ALL) cells expressing HA-AMPKα2 (CN2) under normal and energy/metabolic stress conditions. CN2 cells show significantly altered AMPKα2 genomic binding and transcriptomic profile under metabolic stress conditions, including reduced histone gene expression. Proteomic analysis and in vitro kinase assays identified the TATA-Box–Binding Protein–Associated Factor 1 (TAF1) as a novel AMPKα2 substrate that downregulates histone gene transcription in response to energy/metabolic stress. Knockdown and knockout studies demonstrated that both AMPKα2 and TAF1 are required for histone gene expression. Mechanistically, upon activation, AMPKα2 phosphorylates TAF1 at Ser-1353 which impairs TAF1 interaction with RNA polymerase II (Pol II), leading to a compromised state of p-AMPKα2/p-TAF1/Pol II chromatin association and suppression of transcription. This mechanism was also observed in primary ALL cells and in vivo in NSG mice. Consequently, we uncovered a non-canonical function of AMPK that phosphorylates TAF1, both members of a putative chromatin-associated transcription complex that regulate histone gene expression, among others, in response to energy/metabolic stress.
Implications:
Fully delineating the protein interactome by which AMPK regulates adaptive survival responses to energy/metabolic stress, either via epigenetic gene regulation or other mechanisms, will allow the rational development of strategies to overcome de novo or acquired resistance in ALL and other cancers.
Supplementary Table S6 from A Novel Saliva and Serum miRNA Panel as a Potential Useful Index for Oral Cancer and the Association of miR-21 with Smoking History: a Pilot Study
Authors: Vageli Dimitra P. , Doukas Panagiotis G. , Shah Rema , Boyi Trinithas , Liu Christina , Judson Benjamin L.
Published: December 2023

Supplementary Table S6 shows saliva, serum, and their combined (saliva/serum) miRNA levels in early-stage and late-stage OSCC, and their relative expression compared to healthy controls (HC), in total patients, non-smokers and smokers.
Supplementary Table S4 from A Novel Saliva and Serum miRNA Panel as a Potential Useful Index for Oral Cancer and the Association of miR-21 with Smoking History: a Pilot Study
Authors: Vageli Dimitra P. , Doukas Panagiotis G. , Shah Rema , Boyi Trinithas , Liu Christina , Judson Benjamin L.
Published: December 2023

Supplementary Table S4 shows serum miRNAs and saliva/serum miRNA profiles significantly alerted in OSCC versus healthy controls.
Table S1 from Clinical Performance of hrHPV Primary Screening Using Vaginal versus Cervical Samples to Detect High-grade Intraepithelial Lesions
Authors: King Jonathan , Flores Yvonne N. , Meneses-León Joacim , Hernández-Salazar Sonia , Robles-Rivera Karina , Rivera-Paredez Berenice , León-Maldonado Leith , Hernández-López Rubí , Torres-Ibarra Leticia , Lazcano-Ponce Eduardo , Salmerón Jorge
Published: December 2023

Table S1 presents clinical performance and diagnostic efficiency metrics of three triage strategies for detection of CIN2+ among women screened in Tlalpan, Mexico with positive hrHPV results by sampling method. It is essentially Table 3 for the CIN2+ endpoint.
Supplementary Table S9 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant
Authors: Wang Bo , Ou Ziwei , Zhong Wenlong , Huang Lin , Liao Wenjian , Sheng Yiyu , Guo Zhixing , Chen Junyu , Yang Wenjuan , Chen Ke , Huang Xiaodong , Yang Tenghao , Lin Tianxin , Huang Jian
Published: December 2023

Key resource
Supplementary Figures from Long-Read Sequencing Reveals Alternative Splicing-Driven, Shared Immunogenic Neoepitopes Regardless of SF3B1 Status in Uveal Melanoma
Authors: Yao Tengteng , Zhang Zhe , Li Qian , Huang Rui , Hong Yanhong , Li Chen , Zhang Feng , Huang Yingying , Fang Yan , Cao Qin , Jin Xiaoliang , Li Chunliang , Wang Zefeng , Lin Xinhua (James) , Li Lingjie , Wei Wu , Wang Zhaoyang , Shen Jianfeng
Published: December 2023

Supplementary Figures and legends
Supplementary Table S7 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant
Authors: Wang Bo , Ou Ziwei , Zhong Wenlong , Huang Lin , Liao Wenjian , Sheng Yiyu , Guo Zhixing , Chen Junyu , Yang Wenjuan , Chen Ke , Huang Xiaodong , Yang Tenghao , Lin Tianxin , Huang Jian
Published: December 2023

Primers used for preparation of MV RNAs
Supplementary Table S5 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant
Authors: Wang Bo , Ou Ziwei , Zhong Wenlong , Huang Lin , Liao Wenjian , Sheng Yiyu , Guo Zhixing , Chen Junyu , Yang Wenjuan , Chen Ke , Huang Xiaodong , Yang Tenghao , Lin Tianxin , Huang Jian
Published: December 2023

Clinicopathological characteristics of Cohort Ⅴ patients with urothelial cell carcinoma of the bladder
Supplementary Table S4 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant
Authors: Wang Bo , Ou Ziwei , Zhong Wenlong , Huang Lin , Liao Wenjian , Sheng Yiyu , Guo Zhixing , Chen Junyu , Yang Wenjuan , Chen Ke , Huang Xiaodong , Yang Tenghao , Lin Tianxin , Huang Jian
Published: December 2023

Clinicopathological characteristics of Cohort Ⅳ patients with urothelial cell carcinoma of the bladder
Supplementary Table S3 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant
Authors: Wang Bo , Ou Ziwei , Zhong Wenlong , Huang Lin , Liao Wenjian , Sheng Yiyu , Guo Zhixing , Chen Junyu , Yang Wenjuan , Chen Ke , Huang Xiaodong , Yang Tenghao , Lin Tianxin , Huang Jian
Published: December 2023

Clinicopathological characteristics of Cohort Ⅲ patients with urothelial cell carcinoma of the bladder
Supplemental Figure 9 from Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy
Authors: Nowicki Theodore S. , Peters Cole W. , Quiros Crystal , Kidd Conner K. , Kawakami Moe , Klomhaus Alexandra M. , Baselga-Carretero Ignacio , Kaplan-Lefko Paula , Macabali Mignonette H. , Perez Garcilazo Ivan , Berent-Maoz Beata , Comin-Anduix Begoña , Ribas Antoni
Published: December 2023

Association between CD8 p-NF-B p65 FSI and intracellular IFN- FSI and clinical response to transgenic TCR T cell therapy. Tonic p-NF-B p65 FSI associations between peak change in tumor burden (A) and overall survival (B). Tonic intracellular IFN- FSI associations between peak change in tumor burden (C) and overall survival (D).
Supplementary Table S12 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant
Authors: Wang Bo , Ou Ziwei , Zhong Wenlong , Huang Lin , Liao Wenjian , Sheng Yiyu , Guo Zhixing , Chen Junyu , Yang Wenjuan , Chen Ke , Huang Xiaodong , Yang Tenghao , Lin Tianxin , Huang Jian
Published: December 2023

Demographics of Cohort Ⅱ UCB Patients and tumor characteristics stratified by VISTA expression on immune cells
Supplementary Table S11 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant
Authors: Wang Bo , Ou Ziwei , Zhong Wenlong , Huang Lin , Liao Wenjian , Sheng Yiyu , Guo Zhixing , Chen Junyu , Yang Wenjuan , Chen Ke , Huang Xiaodong , Yang Tenghao , Lin Tianxin , Huang Jian
Published: December 2023

Univariate and multivariate analysis for OS in Cohort Ⅱ UCB Patients
Supplementary Figure S8 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant
Authors: Wang Bo , Ou Ziwei , Zhong Wenlong , Huang Lin , Liao Wenjian , Sheng Yiyu , Guo Zhixing , Chen Junyu , Yang Wenjuan , Chen Ke , Huang Xiaodong , Yang Tenghao , Lin Tianxin , Huang Jian
Published: December 2023

Combination (combo) of VISTA mAb 13F3/sODN-dsRNA with TGF-β1mAb induced TME changes in MB49 mouse tumors
Supplementary Figure S5 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant
Authors: Wang Bo , Ou Ziwei , Zhong Wenlong , Huang Lin , Liao Wenjian , Sheng Yiyu , Guo Zhixing , Chen Junyu , Yang Wenjuan , Chen Ke , Huang Xiaodong , Yang Tenghao , Lin Tianxin , Huang Jian
Published: December 2023

Overall survival (OS) was analyzed for different cellular resource of VISTA on immune cells (ICs) in Cohort Ⅵ UCB patients
Supplementary Figure S4 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant
Authors: Wang Bo , Ou Ziwei , Zhong Wenlong , Huang Lin , Liao Wenjian , Sheng Yiyu , Guo Zhixing , Chen Junyu , Yang Wenjuan , Chen Ke , Huang Xiaodong , Yang Tenghao , Lin Tianxin , Huang Jian
Published: December 2023

Identification of the cellular source of VISTA in MB49 tumors.